Insitro IPO
Insitro is a drug discovery company that uses machine learning and data science to identify new medicines and predict their effectiveness. The company combines high-throughput biology with AI to accelerate pharmaceutical development and reduce the traditional costs and timelines associated with bringing new drugs to market.
What We Know
Insitro has raised substantial venture funding, including a $400 million Series C round in 2022 that valued the company at approximately $2.4 billion. The company has established partnerships with major pharmaceutical companies like Bristol Myers Squibb and Roche. While no IPO timeline has been announced, the company's significant valuation and innovative AI-driven drug discovery platform make it a potential candidate for public markets in the future. The company continues to advance its pipeline and technology platform while remaining privately held.
Frequently Asked Questions
Has Insitro had an IPO?
No, Insitro has not had an IPO and remains a private company. The company has raised significant venture funding but has not announced plans to go public.
When is the Insitro IPO date?
No IPO date has been announced for Insitro. The company continues to operate as a private entity with no confirmed timeline for public market entry. Sign up for alerts to stay informed.
How can I buy Insitro stock?
Insitro stock is not currently available for purchase as the company remains private. Shares may only be available through private markets or accredited investor channels. Sign up for alerts to stay informed.
Stay Updated on the Insitro IPO
Get real-time alerts when Insitro files for an IPO, prices shares, or begins trading.
Get IPO Alerts